Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - MeVis Medical Solutions AG: Approval of the domination and profit and loss transfer agreement with the VMS Deutschland Holdings GmbH

Company: MeVis Medical Solutions AG Date: 2015-09-30 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 News Details

Corporate | 30 September 2015 14:47

#   

MeVis Medical Solutions AG: Approval of the domination and profit and loss transfer agreement with the VMS Deutschland Holdings GmbH

  

DGAP-News: MeVis Medical Solutions AG / Key word(s): Miscellaneous  

  

2015-09-30 / 14:47  

- - -

**Bremen, September 30, 2015 –** Yesterday’s extraordinary general meeting of MeVis Medical Solutions AG resolved to approve the domination and profit and loss transfer agreement between the VMS Deutschland Holdings GmbH as the controlling company and MeVis Medical Solutions AG as the controlled company. The proposed resolution was approved by a majority of 98.40 % of all shareholders present or represented. In order to become effective, the domination and profit and loss transfer agreement requires registration with the commercial register.

Marcus Kirchhoff, CEO of MeVis Medical Solutions AG, pointed out: “The approval of the domination and profit and loss transfer agreement is an important milestone for the future of MeVis. It allows a close cooperation between MeVis and the Varian Group as well as the implementation of standardized organizational structures and strategies in this legal framework.” Dr. Robert Hannemann, CFO of the Company, adds: “The contract also provides special protection measures for minority shareholders, such as the entitlement to receive an annual compensation of EUR 1.13 gross / EUR 0.95 net per share or the option to transfer MeVis shares to the VMS at a price of EUR 19.77.”

  

  

  

- - -

2015-09-30 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.  

The issuer is solely responsible for the content of this announcement.  

  

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.  

Media archive at www.dgap-medientreff.de and www.dgap.de  

- - -

  

|     |     |
| --- | --- |
| Language: | English |
| Company: | MeVis Medical Solutions AG |
|     | Caroline-Herschel-Str. 1 |
|     | 28359 Bremen |
|     | Germany |
| Phone: | +49 421 224 95 0 |
| Fax: | +49 421 224 95 999 |
| E-mail: | ir@mevis.de |
| Internet: | http://www.mevis.de |
| ISIN: | DE000A0LBFE4 |
| WKN: | A0LBFE |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart |
|     |     |     |

|     |     |
| --- | --- |
|     |     |
| End of News | DGAP News Service |

|     |
| --- |
| - - - |
| 398863  2015-09-30 |